ANDA 202827, held by Hikma Pharmaceuticals. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 202827 (Lisdexamfetamine Dimesylate), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 25, 2023, with 4 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate10MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Jul 16, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 16, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 16, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 17, 2024 | Supplement 1Manufacturing | Approved | None posted |
| Aug 25, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters